J. Bostwick

发表

Biomarker Optimization to Track the Antithrombotic and Hemostatic Effects of Clopidogrel in Rats

R. Rehfuss, P. Wong, M. Ogletree, 2007, Journal of Pharmacology and Experimental Therapeutics.

Platelet Aggregometry and Receptor Binding to Predict the Magnitude of Antithrombotic and Bleeding Time Effects of Clopidogrel in Rabbits

R. Rehfuss, P. Wong, M. Ogletree, 2007, Journal of cardiovascular pharmacology.

Pharmacological characterization of a novel factor Xa inhibitor, FXV673.

C. Dunwiddie, R. Bentley, D. Colussi, 2001, Thrombosis research.

Anti-thrombotic activity of RG13965, a novel platelet fibrinogen receptor antagonist.

C. Dunwiddie, J. Cook, J. Bostwick, 1996, Thrombosis research.

Antithrombotic activity of a linear conformationally flexible RGD mimic

Z. Ruggeri, J. Cook, J. Bostwick, 1993 .

Antithrombotic and hemostatic effects of a small molecule factor XIa inhibitor in rats.

E. Liu, M. Ogletree, W. Schumacher, 2007, European journal of pharmacology.

Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding

J. Guay, D. Seiffert, M. Bouvier, 2017, Science Translational Medicine.

Antithrombotic efficacy of RPR208566, a novel factor Xa inhibitor, in a rat model of carotid artery thrombosis.

R. Bentley, D. Colussi, J. Bostwick, 2000, European journal of pharmacology.

Comparison of Enoxaparin, Hirulog, and Heparin as Adjunctive Antithrombotic Therapy during Thrombolysis with rtPA in the Stenosed Canine Coronary Artery

C. Dunwiddie, R. Bentley, M. McVey, 1997, Thrombosis and Haemostasis.

Identification of 1-{2-[4-chloro-1'-(2,2-dimethylpropyl)-7-hydroxy-1,2-dihydrospiro[indole-3,4'-piperidine]-1-yl]phenyl}-3-{5-chloro-[1,3]thiazolo[5,4-b]pyridin-2-yl}urea, a potent, efficacious and orally bioavailable P2Y(1) antagonist as an antiplatelet agent.

P. Lam, Hong Shen, A. Mathur, 2014, Bioorganic & medicinal chemistry letters.

Discovery of diarylurea P2Y(1) antagonists with improved aqueous solubility.

P. Lam, R. Rehfuss, D. Seiffert, 2013, Bioorganic & medicinal chemistry letters.

Discovery of 2-(phenoxypyridine)-3-phenylureas as small molecule P2Y1 antagonists.

J. Y. Roberge, D. Schnur, A. Cacace, 2013, Journal of medicinal chemistry.

Superiority of enoxaparin over heparin in combination with a GPIIb/IIIa receptor antagonist during coronary thrombolysis in dogs.

R. Bentley, S. Rebello, J. Bostwick, 2001, Thrombosis research.

Effect of the Direct Factor Xa Inhibitor Apixaban in Rat Models of Thrombosis and Hemostasis

B. Xin, P. Wong, W. Schumacher, 2010, Journal of cardiovascular pharmacology.

Inhibition of repetitive thrombus formation in the stenosed canine coronary artery by enoxaparin, but not by unfractionated heparin.

C. Dunwiddie, R. Bentley, J. Bostwick, 1998, Arteriosclerosis, thrombosis, and vascular biology.

Design of a new class of orally active fibrinogen receptor antagonists.

C. Dunwiddie, R. Bentley, J. Bostwick, 1998, Journal of medicinal chemistry.

Conformationally constrained ortho-anilino diaryl ureas: discovery of 1-(2-(1'-neopentylspiro[indoline-3,4'-piperidine]-1-yl)phenyl)-3-(4-(trifluoromethoxy)phenyl)urea, a potent, selective, and bioavailable P2Y1 antagonist.

Steven A. Spronk, P. Lam, D. Schnur, 2013, Journal of medicinal chemistry.

Pharmacodynamic activity and antithrombotic efficacy of RPR120844, a novel inhibitor of coagulation factor Xa.

C. Dunwiddie, R. Bentley, A. Spada, 1999, Journal of cardiovascular pharmacology.

RPR120844, a Novel, Specific Inhibitor of Coagulation Factor Xa Inhibits Venous Thrombosis in the Rabbit

C. Dunwiddie, R. Bentley, A. Spada, 1999, Thrombosis and Haemostasis.

Linking (Pyr)1apelin-13 pharmacokinetics to efficacy: Stabilization and measurement of a high clearance peptide in rodents.

Michael C. Myers, Rongan Zhang, P. Gargalovic, 2019, Analytical biochemistry.

Biphenyl Acid Derivatives as APJ Receptor Agonists.

Michael A. Galella, P. Gargalovic, D. Gordon, 2019, Journal of medicinal chemistry.

Design and structure-activity relationships of potent and selective inhibitors of blood coagulation factor Xa.

D L Cheney, C. Dunwiddie, J. Mason, 1999, Journal of medicinal chemistry.

Synthesis, SAR and in vivo activity of novel thienopyridine sulfonamide pyrrolidinones as factor Xa inhibitors.

R. Bentley, A. Spada, C. Ly, 1999, Bioorganic & medicinal chemistry letters.

RG 12915: a potent 5-hydroxytryptamine-3 antagonist that is an orally effective inhibitor of cytotoxic drug-induced emesis in the ferret and dog.

L. Fitzpatrick, C. Pendley, G. Martin, 1990, The Journal of pharmacology and experimental therapeutics.

Antiinflammatory effects of various drugs on acetic acid induced colitis in the rat

L. Fitzpatrick, R. Pendleton, J. Bostwick, 1990, Agents and Actions.

Bleeding response induced by anti-thrombotic doses of a phosphoinositide 3-kinase (PI3K)-β inhibitor in mice.

P. Shipkova, J. E. Bird, W. Schumacher, 2011, Thrombosis research.

Is exogenous tissue plasminogen activator necessary for antithrombotic efficacy of an inhibitor of thrombin activatable fibrinolysis inhibitor (TAFI) in rats?

E. Bird, J. Tamasi, J. Feyen, 2007, Thrombosis research.

Restenosis following angioplasty in the swine coronary artery is inhibited by an orally active PDGF-receptor tyrosine kinase inhibitor, RPR101511A.

C. Dunwiddie, A. Spada, P. Persons, 1999, Circulation.

Identification of 6-Hydroxypyrimidin-4(1H)-one-3-carboxamides as Potent and Orally Active APJ Receptor Agonists.

P. Gargalovic, D. Gordon, R. Wexler, 2021, ACS medicinal chemistry letters.

Identification of 6-Hydroxy-5-phenylsulfonylpyrimidin-4(1H)-one APJ Receptor Agonists.

Michael A. Galella, P. Gargalovic, R. Wexler, 2021, Bioorganic & Medicinal Chemistry Letters.

4‐Benzothiazole‐7‐hydroxyindolinyl Diaryl Ureas Are Potent P2Y1 Antagonists with Favorable Pharmacokinetics: Low Clearance and Small Volume of Distribution

Steven A. Spronk, P. Lam, Hong Shen, 2014, ChemMedChem.

Identification of a Hydroxypyrimidinone Compound (21) as a Potent APJ Receptor Agonist for the Potential Treatment of Heart Failure.

P. Gargalovic, R. Wexler, Tao Wang, 2021, Journal of medicinal chemistry.

Discovery of a Hydroxypyridinone APJ Receptor Agonist as a Clinical Candidate.

Michael A. Galella, P. Gargalovic, Soong-Hoon Kim, 2021, Journal of medicinal chemistry.

Discovery of Potent and Selective Quinoxaline-Based Protease-Activated Receptor 4 (PAR4) Antagonists for the Prevention of Arterial Thrombosis.

Shana L. Posy, R. Wexler, J. M. Richter, 2024, Journal of medicinal chemistry.